The Latest Cardiac and Vascular News
EMERYVILLE, Calif.–(BUSINESS WIRE)–Fauna Bio, a biotechnology company improving human health by leveraging animal genomics, today announced Faun1083 as its first development candidate. Discovered through Fauna Bio’s proprietary Convergence™ drug discovery platform, Faun1083 is a potential first-in-class therapeutic targeting heart failure with preserved ejection fraction (HFpEF), a disease with currently limited […]
TORONTO, Jan. 08, 2025 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the University Health Network Research Ethics Board, through the Clinical Trials Ontario Streamlined Research Ethics Review System, has granted provincial ethics approval for the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).
TORONTO, Jan. 07, 2025 (GLOBE NEWSWIRE) — Conavi Medical Corp. (TSXV: CNVI; OTC: CNVIF) (“Conavi Medical” or the “Company”), a commercial stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, is pleased to announce the publication of a detailed review of its collaboration with U.S.-based Minnetronix, a world leader in high-precision medical device manufacturing. Published in the industry journal, Medical Design & Development, the article was co-authored by Tom Looby, Conavi Medical’s CEO and Darcy Hart, Minnetronix Medical’s Director of Optical Products.
Medtronic plc, a global leader in healthcare technology, today announced it received CE (Conformité Européenne) Mark for the Harmony™ Transcatheter Pulmonary Valve (TPV) System, a minimally invasive alternative to open-heart surgery for congenital heart disease patients with native or surgically repaired right ventricular outflow tract (RVOT). The Harmony TPV system […]
– Developed first-of-its-kind unshielded MCG device for bedside use, published in MDPI Sensors – Presented AI applications in MCG at Frontiers of Cardiovascular Medicine special issue – Breakthrough clinical results on N-STEMI diagnostics presented at AHA Scientific Sessions – Launched…
TEL AVIV, Israel, Dec. 26, 2024 /PRNewswire/ — Microtech, a wholly owned subsidiary of Medinol Inc., a leader in global MedTech research and development, announced that it has initiated human clinical trials of their microsensor platform, in a trial to measure atrial pressures important…
Commercial validation in Europe parallels ongoing RESPONDER-HF clinical trial TEWKSBURY, Mass., Dec. 20, 2024 /PRNewswire/ — Corvia Medical, Inc., a company dedicated to transforming the treatment of heart failure, announced today that it has achieved CE certification for the Corvia®…
Roivios Initiates Landmark Study to Demonstrate Safety and Efficacy of an Innovative Renal Assist Device for Cardiac Surgery Patients With Kidney Disease NASSAU, Bahamas, Dec. 19, 2024 /PRNewswire/ — Roivios, a pioneering clinical-stage medical device company dedicated to revolutionizing…
– Exclusive rights secured related to the development of a potential disease-modifying therapeutic for cardiovascular disease. CHICAGO, Dec. 19, 2024 /PRNewswire/ — Xentria, Inc. (Xentria), a clinical-stage biotherapeutics company focused on advancing drug development to address unmet…
HUNTINGTON BEACH, Calif.–(BUSINESS WIRE)–BiVACOR, a clinical-stage medical device company, announced today, the successful completion of the first phase of the FDA Early Feasibility Study, with five patients receiving the BiVACOR Total Artificial Heart (TAH) between July and November 2024. The study evaluates the safety and performance of the BiVACOR TAH System […]
